Multiple Sclerosis – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of multiple sclerosis (MS) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of MS for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy in the major mature pharmaceutical markets.
Clarivate Epidemiology’s MS forecast will answer the following questions:
- Of all people diagnosed with MS, how many in each country in the developed world are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of MS over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts 16 MS patient populations, including the following:
- Diagnosed prevalent cases of relapsing-remitting multiple sclerosis (RR-MS).
- Diagnosed prevalent cases of primary-progressive multiple sclerosis (PP-MS).
- Diagnosed prevalent cases of secondary-progressive multiple sclerosis (SP-MS).
- Diagnosed prevalent cases of clinically isolated syndrome (CIS).
- Diagnosed incident cases of RR-MS.
- Diagnosed incident cases of CIS.
- Drug-treated prevalent cases of RR-MS.
- Drug-treated prevalent cases of PP-MS.
- Drug-treated prevalent cases of SP-MS.
- Drug-treated prevalent cases of CIS.
- … and many more (details available on request).
Note: Coverage may vary by country.
Table of contents
- Multiple Sclerosis - Epidemiology - Mature Markets
- Epidemiology data
- Methods
- Literature review (studies included in / excluded from the analyses of multiple sclerosis)
- Diagnosed prevalent cases
- Diagnosed incident cases
- Diagnosed prevalent cases by disease subtype
- Diagnosed incident cases by disease subtype
- Diagnosed prevalent cases by treatment scheme
- Risk / protective factors applied to disease forecast models
- Reference materials
- Bibliography
- Glossary
- Abbreviations
Navya Vardhan, M.Sc., Epidemiologist, Epidemiology. She obtained her M.Sc. in biostatistics and demography from the International Institute for Population Sciences in Mumbai. She also holds a B.Sc. in mathematics.
Stephanie Niquita Phankon, M.B.B.S., M.P.H., Manager, Epidemiology. Ms. Phankon’s expertise is in autoimmune and inflammatory diseases and hematological malignancies. She holds a master’s in public health specializing in epidemiology from TISS in Mumbai and a medical degree from Hubei University of Chinese Medicine in the People’s Republic of China. She has been trained as a community physician and has supervised and coordinated various governmental and nongovernmental public health projects.